LONDON - Shares in Oxford GlycoSciences plc fell by 92.5 pence to £3 Monday after the company said the FDA had ruled its lead product, Vevesca, not approvable. At that price the market capitalization of OGS is less than its £170 million (US$255 million) cash pile. (BioWorld International)

LONDON - Shares in Oxford GlycoSciences plc fell by 92.5 pence to £3 Monday after the company said the FDA had ruled its lead product, Vevesca, not approvable. At that price the market capitalization of OGS is less than its £170 million (US$255 million) cash pile. (BioWorld International)